Device Trial Radar · NCT04697004
SMR Stemless Reverse vs SMR Reverse Shoulder System
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Apr 1, 2021
Primary completion
Dec 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Limacorporate S.p.aNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- NAMSA
- First posted
- Jan 6, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function. This is a prospective, multi-center, randomized, controlled trial to demonstrate non-inferiority of the SMR Stemless Reverse to the SMR Reverse Shoulder System. Patients with joint dysfunction who continue to experience significant symptoms despite an appropriate course of non-operative management are eligible. Patients will be considered enrolled into the study when an ICF has been signed, all inclusion criteria are met and no exclusion criteria are present including intraoperative exclusion criteria, and the patient is randomized into either the SMR Stemless Reverse (investigational) group, the SMR Reverse Shoulder System (control) group or is part of the roll-in population. Enrollment is expected to take approximately 24 months.
Conditions
- Arthroplasty, Replacement
Interventions
Investigational Arm: SMR Stemless ReverseDevice
The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function.
Control Arm: SMR Reverse Shoulder SystemDevice
Conventional stemmed shoulder prostheses are commonly used in the clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Efficacy Endpoint-Constant Murley ScoreTime frame: 24 Months
1 more outcomes with a free account
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Kerlan-Jobe Institute
Los Angeles, California · Withdrawn
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.